Brokerages expect that KemPharm Inc (NASDAQ:KMPH) will report ($0.48) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for KemPharm’s earnings. The lowest EPS estimate is ($0.55) and the highest is ($0.41). KemPharm reported earnings per share of ($0.72) in the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The firm is expected to announce its next earnings report on Thursday, April 4th.
On average, analysts expect that KemPharm will report full-year earnings of ($3.85) per share for the current fiscal year, with EPS estimates ranging from ($4.04) to ($3.65). For the next year, analysts forecast that the firm will report earnings of ($1.41) per share, with EPS estimates ranging from ($1.61) to ($1.20). Zacks’ earnings per share averages are an average based on a survey of analysts that cover KemPharm.
Get KemPharm alerts:
KMPH has been the topic of a number of recent research reports. Oppenheimer set a $10.00 target price on KemPharm and gave the stock a “buy” rating in a report on Thursday, November 15th. Zacks Investment Research downgraded KemPharm from a “buy” rating to a “hold” rating in a report on Wednesday, November 21st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $10.60.
Institutional investors and hedge funds have recently modified their holdings of the stock. Janney Montgomery Scott LLC bought a new position in KemPharm during the fourth quarter valued at about $44,000. Change Path LLC bought a new position in KemPharm during the fourth quarter valued at about $67,000. Northern Trust Corp increased its stake in KemPharm by 34.0% during the fourth quarter. Northern Trust Corp now owns 43,445 shares of the specialty pharmaceutical company’s stock valued at $78,000 after acquiring an additional 11,014 shares during the period. BlackRock Inc. increased its stake in KemPharm by 25.0% during the fourth quarter. BlackRock Inc. now owns 90,426 shares of the specialty pharmaceutical company’s stock valued at $161,000 after acquiring an additional 18,079 shares during the period. Finally, Bridgeway Capital Management Inc. bought a new position in KemPharm during the third quarter valued at about $264,000. Hedge funds and other institutional investors own 19.61% of the company’s stock.
Shares of KMPH traded down $0.04 during midday trading on Friday, reaching $2.30. The stock had a trading volume of 72,252 shares, compared to its average volume of 79,903. KemPharm has a 52 week low of $1.72 and a 52 week high of $8.40. The company has a market capitalization of $61.36 million, a PE ratio of -0.78 and a beta of 1.85.
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.
Read More: Asset Allocation and Your Retirement
Get a free copy of the Zacks research report on KemPharm (KMPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com